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HOXC9Induction of differentiation is a therapeutic strategy in neuroblastoma, a common pediatric cancer of the sympa-
thetic nervous system. The homeobox protein HOXC9 is a key regulator of neuroblastoma differentiation. To gain
amolecular understanding of the function ofHOXC9 in promotingdifferentiation of neuroblastoma cells, we con-
ducted a genome-wide analysis of the HOXC9-induced differentiation program by microarray gene expression
proﬁling and chromatin immunoprecipitation in combination with massively parallel sequencing (ChIP-seq).
Herewedescribe in detail the experimental system,methods, and quality control for the generation of themicro-
array and ChIP-seq data associated with our recent publication [1].
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Cell line
The human neuroblastoma cell line BE(2)-C was obtained from
ATCC (CRL-2268, ATCC). BE(2)-C cells carry p53 mutation and MYCN
ampliﬁcation [2,3]. It has been shown previously that this cell line con-
tains a subpopulation of neuroblastoma cells capable of self-renewal
and multi-lineage differentiation [4,5]. BE(2)-C cells can differentiate
into neurons following treatment with retinoic acid (RA) [4–7] or into
Schwann-like cells when treated with bromodeoxyuridine [4,5,8]. As a
result, BE(2)-C cells have been used as a model system for investigating
agents and signaling pathways that control neuroblastoma cell differen-
tiation, which represents a promising therapeutic strategy for neuro-
blastoma [9,10].
We have recently identiﬁed HOXC9 as a downstream target gene
of RA and an essential mediator of RA action in neuroblastoma
differentiation: HOXC9 expression is upregulated by RA and knock-
down of HOXC9 expression confers resistance to RA-induced differenti-
ation. Moreover, HOXC9 induction can fully recapitulate the phenotype
of RA treatment [7]. To gain a molecular understanding of the mecha-
nism by which HOXC9 induces the neuronal differentiation of neuro-
blastoma cells, we generated BE(2)-C-derived cells with inducible
expression of myc-tagged human HOXC9 in the absence of doxycycline,
using the Retro-X Tet-Off Advanced Inducible Gene Expression System
(Clontech).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Quality assessment of ChIP-seq data. (A) BoxWhisker type plot showing per-base sequence quality scores for read 1 (positive strand, left panel) and read 2 (negative strand, right
panel). Higher score indicates better quality. (B) Quality assessment of sequencing sufﬁciency using histogram and cumulative fraction of base quality scores in peaks. (C) Tag density plot
showing the average of the normalized tag densities for all RefSeq genes. HOXC9-binding sites are highly enriched around TSS. TTS, transcription termination sites.
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To identify the genes that are regulated by HOXC9, we isolated total
RNA from three independent samples of BE(2)-C/Tet-Off/myc-HOXC9
cells cultured in the presence or absence of doxycycline for 6 days
using Trizol (Invitrogen). The quantity and quality of the RNA samples
were measured and assessed by a NanoDrop spectrophotometer and
Agilent 2100 Bioanalyzer (Agilent Technologies). Affymetrixmicroarray
analysis was performed using the Human Gene 1.0 ST microarray chip.
The quality of each CEL ﬁle was assessed using Affymetrix Expres-
sion Console Software according to the Affymetrix standard protocol
(Quality Assessment of Exon and Gene 1.0 ST Arrays, Affymetrix
White Paper, 2007). Relative log expression (RLE) was used to identify
outlier samples. In order to monitor labeling and hybridization quality,
we used polyA-control RNAs (Lys, Phe, Thr and Dap) and bacterial
spike-in controls (BioB, BioC, BioD and Cre), respectively.
CEL ﬁles were imported into Partek Genomics Suit using RMA nor-
malization. The probesets were annotated using the HuGene-1_0-st-
v1 Probeset Annotations and Transcript Cluster Annotations. The differ-
ential expressions were calculated using ANOVA of the Partek package.ChIP
To identify the genomic sites that are bound by HOXC9, we per-
formed two independent ChIP-seq assays with BE(2)-C/Tet-Off/myc-HOXC9 cells cultured in the absence of doxycycline for 6 days according
to the published procedure [11]. Brieﬂy, 4 × 107 cells were ﬁxedwith 1%
formaldehyde for 10min and quenchedwith 0.125M glycine for 5min.
After cell lysis, cross-linked chromatin DNA was sheared
to approximately 250 bp by sonication (Model 150E ultrasonic dis-
membrator, Fisher Scientiﬁc), and immunoprecipitated with 10 μg of
mouse anti-myc tag (clone 4A6, Millipore) and 80 μl Dynabeads Protein
G (Invitrogen). The immunoprecipitated HOXC9–DNA complexes were
washed extensively and eluted with SDS buffer, followed by incubation
overnight at 65 °C to reverse cross-linking. The sampleswere then treat-
ed sequentially with RNase A and proteinase K to degrade associated
RNA and proteins, and ChIP DNA was puriﬁed by phenol–chloroform
extraction and ethanol precipitation. Input genomic DNA was puriﬁed
from an aliquot of chromatin after sonication. DNA concentration was
determinedusing a PicoGreendsDNAquantitation assay kit (Invitrogen).
ChIP library and quality control
ChIP libraries were generated according to the Illumina ChIP-seq
library construction procedure. Brieﬂy, 10 ng of ChIP DNA was end
repaired with T4 DNA polymerase, Klenow fragment and T4 polynucle-
otide kinase (all from Enzymatics), and an adenosine base was then
added to the 3′ end of the blunt phosphorylated DNA fragments by
Klenow fragment (3′→ 5′ exo-) (Enzymatics). This was followed by
ligation of Illumina genomic adapters. Ligated DNA around the size of
250–300 bp was isolated by electrophoresis through a 3% NuSieve 3:1
Fig. 2.HOXC9-induced neuroblastoma cell differentiation is characterized by reduced production of biosynthetic precursors. Gene ontology analysis of downregulated HOXC9-responsive
genes reveals the enrichment of genes involved in the biosynthesis of nucleotides, sterol, and amino acids (enrichment fold N2.0, p b 0.001).
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mo Scientiﬁc). The PCR products were then puriﬁed using an Agencourt
Ampure kit (Beckman Coulter) to remove primer dimmers.
Agilent 2100 Bioanalyzer was employed to examine the normal
size distribution and possible primer or linker contamination of each
library. The library concentration was measured using both Qubit
dsDNA BR Assay Kit (Invitrogen) and real-time qPCR method. Real-
time qPCR was performed on StepOne Plus Real-Time PCR systems
(Applied Biosystems) using KAPA SYBR FAST universal qPCR kit
(KAPA Biosystems). qPCR primers, 1.1 and 2.1, were designed based
on Illumina Sequencing Library qPCR Quantiﬁcation Guide. PhiX Con-
trol v3 (Illumina) was used in the reaction to plot the standard curve.
ChIP-seq data quality control
ChIPDNAwas sequenced using IlluminaGenomeAnalyzer IIXwith a
read length of 36 (paired-end).Weperformed several analyses to assess
the quality of the sequencing data. Boxwhisker type plot analysis shows
per base sequence quality scores for read 1 (Fig. 1A, left panel) and read
2 (Fig. 1A, right panel). Red and blue lines represent the median and
mean value, respectively; the yellow box indicates the inter-quartile
range (25–75%); and the upper and lower whiskers indicate the 10%
and 90% points (FASTQC) [12]. Fig. 1B shows the quality assessment of
sequencing sufﬁciency using histogram and cumulative fraction of
base quality scores in peaks. We also analyzed tag density to visualize
the quality of sequencing and mapping, and to examine the global
proﬁle of HOXC9 ChIP-seq based on genes, which shows that HOXC9-
binding peaks are highly enriched around transcription start sites
(TSS) (Fig. 1C).
Discussion
We described here a dataset composed of microarray gene ex-
pression proﬁling of HOXC9-responsive genes and ChIP-seq data for
genome-wide mapping of HOXC9-binding sites in the human neuro-
blastoma BE(2)-C cells. With this dataset, we were able to demonstrate
that HOXC9 directly controls and coordinates the expression of a large
number of genes involved in neuron genesis and differentiation, cell
cycle progression, and DNA damage repair [1]. We believe that this
dataset would be particularly valuable for investigating the cellular
processes associated with differentiation and underlying molecularmechanisms. For example, we found that HOXC9-induced differentia-
tion is associated with a marked reduction in cellular metabolism, as a
result of global downregulation of genes involved in the biosynthesis
of nucleotides, sterol, and amino acids (Fig. 2). This ﬁnding sheds
new light on the interplay between metabolic reprogramming and
cancer cell differentiation, and suggests that reprogramming cellular
metabolism may represent a promising strategy for promoting cancer
cell differentiation.Conﬂict of interest
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